Lumexa Imaging Q4 Revenue $267.73M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy LMRI?
Reports Q4 revenue $267.73M, consensus $261.8M. Same center advanced volume growth: 12.7% for consolidated and 9.2% for system-wide. "The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business," said Caitlin Zulla, CEO of Lumexa Imaging. "Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey. We strengthened our balance sheet, reducing leverage by two turns, and opened a record number of de novo centers during the year, setting the stage for future growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMRI
Wall Street analysts forecast LMRI stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.400
Low
22.00
Averages
22.71
High
23.00
Current: 9.400
Low
22.00
Averages
22.71
High
23.00
About LMRI
Lumexa Imaging Holdings, Inc. is a national provider of diagnostic imaging services. The Company offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The Company and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson Fistel Investigates Lumexa Imaging for Potential Investor Claims
- Financial Loss Disclosure: On March 26, 2026, Lumexa Imaging reported a net loss for both Q4 and the full year of 2025, which significantly undermined investor confidence and led to a sharp decline in stock price during trading.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Lumexa Imaging's executives violated federal securities laws, potentially allowing investors who suffered losses from purchasing the company's securities to seek recovery through legal channels.
- Investor Rights Protection: The law firm focuses on representing individual and institutional investors in shareholder derivative and securities class action lawsuits, aiming to provide legal support and protect the rights of affected investors.
- Past Performance Review: In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Lumexa Imaging Reports Q4 Loss and Revenue Growth
- Financial Overview: Lumexa Imaging reported a net loss of $28.7 million in Q4, up from $25.1 million a year earlier, despite a 7.9% year-over-year revenue increase to $267.7 million, indicating potential in revenue growth but the widening loss may dampen investor confidence.
- Adjusted EBITDA Growth: The company achieved an adjusted EBITDA of $63.8 million, an 18.6% increase from $53.7 million last year, with an adjusted EBITDA margin of 23.8%, demonstrating significant progress in cost control and operational efficiency, although overall financial health still requires improvement.
- Leverage Reduction: Lumexa Imaging successfully reduced its leverage from 5.5 times to 3.5 times, resulting in over $50 million in annual cash savings, which enhances the company's financial flexibility and provides a stronger foundation for future investments and expansion.
- 2026 Outlook: The company reiterated its financial outlook for 2026, expecting consolidated revenues between $1.045 billion and $1.097 billion, with adjusted EBITDA projected at $234 million to $242 million, although the addition of public company costs lowers the adjusted EBITDA growth rate from 7% to 4%, potentially impacting market expectations for future growth.
See More
LUMEXA IMAGING HOLDINGS INC - 2026 REVENUE PROJECTIONS: CONSOLIDATED REVENUES BETWEEN $1.045 AND $1.097 BILLION
Company Overview: LUMEXA Imaging Holdings is a company focused on imaging technologies and solutions.
Financial Performance: The company reported consolidated revenues ranging from $1.045 billion to $1.097 billion for the year 2026.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
U.S. Stock Futures Rise Slightly Amid Earnings Beat
- Earnings Beat: The company reported quarterly earnings of $0.81 per share, surpassing the analyst consensus estimate of $0.77 per share, indicating improved profitability that may boost investor confidence.
- Sales Growth: Quarterly sales reached $14.438 billion, exceeding the analyst consensus estimate of $13.943 billion, demonstrating the company's competitive position and strong product demand in the market.
- Stock Price Movement: Despite the strong earnings report, HP shares dipped 5.2% to $17.25 in pre-market trading, reflecting cautious market sentiment regarding future prospects.
- Market Dynamics: U.S. stock futures rose slightly on Wednesday, with Dow futures gaining around 0.1%, indicating a generally optimistic investor sentiment towards the overall market, though individual stock performances warrant close attention.
See More
Lumexa Imaging to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Lumexa Imaging's CEO Caitlin Zulla and CFO Tony Martin will participate in upcoming investor conferences, showcasing the company's leadership in the imaging sector, which is expected to attract investor interest.
- Business Scale: With over 5,000 employees and 185 outpatient imaging centers nationwide, Lumexa Imaging conducted approximately 4 million outpatient scans in 2024, demonstrating its strong capabilities and market share in the medical imaging services sector.
- Technological Edge: The company is committed to delivering best-in-class clinical excellence, operational efficiency, and state-of-the-art technology, further solidifying its position as the partner of choice for health systems and radiologists, driving future business growth.
- Forward-Looking Statements: The press release includes forward-looking statements regarding future business strategies and management plans, cautioning investors to consider the potential risks and uncertainties associated with these statements.
See More
Johnson Fistel Investigates Lumexa Imaging for Potential Investor Claims
- Financial Loss Disclosure: On March 26, 2026, Lumexa Imaging reported a net loss for both Q4 and the full year of 2025, which significantly undermined investor confidence and led to a sharp decline in stock price during trading.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Lumexa Imaging's executives violated federal securities laws, potentially allowing investors who suffered losses from purchasing the company's securities to seek recovery through legal channels.
- Investor Rights Protection: The law firm focuses on representing individual and institutional investors in shareholder derivative and securities class action lawsuits, aiming to provide legal support and protect the rights of affected investors.
- Past Performance Review: In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms, successfully recovering approximately $90.725 million for clients, demonstrating its effectiveness in advocating for investor rights.
See More
Lumexa Imaging Reports Q4 Loss and Revenue Growth
- Financial Overview: Lumexa Imaging reported a net loss of $28.7 million in Q4, up from $25.1 million a year earlier, despite a 7.9% year-over-year revenue increase to $267.7 million, indicating potential in revenue growth but the widening loss may dampen investor confidence.
- Adjusted EBITDA Growth: The company achieved an adjusted EBITDA of $63.8 million, an 18.6% increase from $53.7 million last year, with an adjusted EBITDA margin of 23.8%, demonstrating significant progress in cost control and operational efficiency, although overall financial health still requires improvement.
- Leverage Reduction: Lumexa Imaging successfully reduced its leverage from 5.5 times to 3.5 times, resulting in over $50 million in annual cash savings, which enhances the company's financial flexibility and provides a stronger foundation for future investments and expansion.
- 2026 Outlook: The company reiterated its financial outlook for 2026, expecting consolidated revenues between $1.045 billion and $1.097 billion, with adjusted EBITDA projected at $234 million to $242 million, although the addition of public company costs lowers the adjusted EBITDA growth rate from 7% to 4%, potentially impacting market expectations for future growth.
See More
LUMEXA IMAGING HOLDINGS INC - 2026 REVENUE PROJECTIONS: CONSOLIDATED REVENUES BETWEEN $1.045 AND $1.097 BILLION
Company Overview: LUMEXA Imaging Holdings is a company focused on imaging technologies and solutions.
Financial Performance: The company reported consolidated revenues ranging from $1.045 billion to $1.097 billion for the year 2026.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
U.S. Stock Futures Rise Slightly Amid Earnings Beat
- Earnings Beat: The company reported quarterly earnings of $0.81 per share, surpassing the analyst consensus estimate of $0.77 per share, indicating improved profitability that may boost investor confidence.
- Sales Growth: Quarterly sales reached $14.438 billion, exceeding the analyst consensus estimate of $13.943 billion, demonstrating the company's competitive position and strong product demand in the market.
- Stock Price Movement: Despite the strong earnings report, HP shares dipped 5.2% to $17.25 in pre-market trading, reflecting cautious market sentiment regarding future prospects.
- Market Dynamics: U.S. stock futures rose slightly on Wednesday, with Dow futures gaining around 0.1%, indicating a generally optimistic investor sentiment towards the overall market, though individual stock performances warrant close attention.
See More
Lumexa Imaging to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Lumexa Imaging's CEO Caitlin Zulla and CFO Tony Martin will participate in upcoming investor conferences, showcasing the company's leadership in the imaging sector, which is expected to attract investor interest.
- Business Scale: With over 5,000 employees and 185 outpatient imaging centers nationwide, Lumexa Imaging conducted approximately 4 million outpatient scans in 2024, demonstrating its strong capabilities and market share in the medical imaging services sector.
- Technological Edge: The company is committed to delivering best-in-class clinical excellence, operational efficiency, and state-of-the-art technology, further solidifying its position as the partner of choice for health systems and radiologists, driving future business growth.
- Forward-Looking Statements: The press release includes forward-looking statements regarding future business strategies and management plans, cautioning investors to consider the potential risks and uncertainties associated with these statements.
See More
